AN2 Therapeutics (ANTX) Income from Non-Controlling Interests (2021 - 2026)
AN2 Therapeutics' (ANTX) quarterly Income from Non-Controlling Interests came in at -$62000.0 in Q1 2026, down 464.71% year-on-year from $17000.0 in Q1 2025, and down 785.71% on a QoQ basis from -$7000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$62000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 464.71% year-over-year to -$62000.0 in Q1 2026; TTM through Mar 2026 was -$53000.0, a 960.0% decrease from a year earlier, with the FY2025 full-year figure at $26000.0, up 110.66% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$62000.0, down from -$7000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for ANTX reached as high as $397000.0 in Q4 2023 and fell as low as -$222000.0 in Q1 2024.
- Historically, Income from Non-Controlling Interests has averaged $1294.1 across 5 years, with a median of -$7000.0 in 2025.
- Across the five-year window, Income from Non-Controlling Interests slumped 5933.33% in 2022 and soared 4733.33% in 2024, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $167000.0 in 2022, then jumped by 137.72% to $397000.0 in 2023, then tumbled by 120.4% to -$81000.0 in 2024, then surged by 91.36% to -$7000.0 in 2025, then plunged by 785.71% to -$62000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$62000.0 in Q1 2026, -$7000.0 in Q4 2025, and $39000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | AN2 Therapeutics | 167.57 Mn | 167.57 Mn | - | -62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | -23,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | -81,000.00 |
| Sep 30, 2024 | 139,000.00 |
| Jun 30, 2024 | -80,000.00 |
| Mar 31, 2024 | -222,000.00 |
| Dec 31, 2023 | 397,000.00 |
| Sep 30, 2023 | -3,000.00 |
| Jun 30, 2023 | 56,000.00 |
| Mar 31, 2023 | 199,000.00 |
| Dec 31, 2022 | 167,000.00 |
| Sep 30, 2022 | -181,000.00 |
| Jun 30, 2022 | -202,000.00 |
| Mar 31, 2022 | -131,000.00 |
| Dec 31, 2021 | -24,000.00 |
| Sep 30, 2021 | -3,000.00 |